Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
PR Newswire - December 7, 1995
Dr. Devens, who holds a doctorate in experimental pathology from the University of California, Los Angeles, has focused his research on immune regulation and the role of the immune system in human disease.
Dr. Devens joins Targeted Genetics from Syntex Discovery Research where he was most recently senior department head of inflammation biology and immunology. At Syntex, he had responsibility for managing products at various stages of development, from the laboratory through FDA approval. He previously held positions as senior scientist, and research investigator in the immunopharmacology department at Hoffmann- La Roche. Prior to that Dr. Devens was assistant professor, biomedical sciences (pathology) and biology at the University of California, Riverside. Before joining UC at Riverside, he was a National Institutes of Health (NIH) Individual Postdoctoral Fellow at Hebrew University- Hadassah Medical School's Lautenberg Center for General and Tumor Immunology. Dr. Devens is a member of the American Association of Immunologists.
"Bruce Devens' experience in immunology, and in successfully managing products at various stages of development will enhance our ability to make and meet our strategic goals," said Barrie J. Carter, Ph.D., executive vice president and director of research and development at Targeted Genetics. "We're fortunate to add his experience to our team."
Targeted Genetics has several product candidates in clinical trials for acquired and inherited diseases, including Human Immunodeficiency Virus (HIV), the virus that causes AIDS, cancer, Gaucher disease, and cystic fibrosis (CF). The company recently began a clinical trial to test a new gene therapy for CF using a novel vector (or delivery system) called an adeno-associated virus (AAV) to carry the normal CF gene into the nose and lung of CF patients.
Targeted Genetics Corporation develops gene and cell therapy products for the treatment of certain acquired and inherited diseases. The company's principal focus is on CTL-based immunotherapy for infectious diseases and cancer, in vivo adeno-associated virus-based therapy for cystic fibrosis, and stem cell gene therapy.
NOTE TO EDITORS: Targeted Genetics' press releases are available at no charge through PR Newswire's Company News On-Call fax service and on PRN's Web site. For a menu of Targeted Genetics press releases or to retrieve a specific release, call 800-758-5804, extension 434644, or http://www.prnewswire.com/cnoc/exec/menu?832075 on the Internet./
CONTACT: Alberta L. Garvin of Targeted Genetics, 206-521-7824/ 09:15 EST
Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951207
PR951215
Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .